Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...
Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...
New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...
The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...
MedPage Today on MSN
mRNA Flu Vaccine Tops Standard Shot in Trial
For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...
A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...
Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback